table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID-19 severe or critically
COVID-19 prophylaxis (excluding children)
Immunostimulants drugs
neutralizing antibody
bamlanivimab monotherapy BLAZE-2 US ...
casirivimab/imdevimab (Ronapreve) Cov-2069 ...
cilgavimab and tixagevimab (Evusheld) Jurdi PROVENT

0 studies excluded by filtering options 2

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons